Evidence map›Paper›PMID 34108036›Full record

ArticleTrials2021

Evaluation of adherence monitoring system using evriMED with a differentiated response compared to standard of care among drug-sensitive TB patients in three provinces in South Africa: a protocol for a cluster randomised control trial.

Noriah Maraba, Catherine Orrell, Candice M Chetty-Makkan, Kavindhran Velen, Rachel Mukora, Liesl Page-Shipp, Pren Naidoo, M Thulani Mbatha, Katherine L Fielding, Salome Charalambous

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Closing gaps through innovation in the tuberculosis pathology value chain.Journal of clinical tuberculosis and other mycobacterial diseases · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Noriah MarabaThe Aurum Institute, Parktown, Johannesburg, South Africa. nmaraba@auruminstitute.org.ORCID http://orcid.org/0000-0002-3974-5961
Catherine OrrellDepartment of Medicine and Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Candice M Chetty-MakkanThe Aurum Institute, Parktown, Johannesburg, South Africa.
Kavindhran VelenThe Aurum Institute, Parktown, Johannesburg, South Africa.
Rachel MukoraThe Aurum Institute, Parktown, Johannesburg, South Africa.
Liesl Page-ShippInteractive Research and Development, Johannesburg, South Africa.
Pren NaidooStellenbosch University, Stellenbosch, South Africa.
M Thulani MbathaInteractive Research and Development, Johannesburg, South Africa.
Katherine L FieldingSchool of Public Health, University of Witwatersrand, Johannesburg, South Africa.
Salome CharalambousThe Aurum Institute, Parktown, Johannesburg, South Africa.
Aurum Institute · ZAUniversity of the Witwatersrand · ZADesmond Tutu HIV Foundation · ZAStellenbosch University · ZA

Funding

Bill and Melinda Gates Foundation OPP1205388South African Medical Research Council,Strategic Health Innovation Partnerships Not availableSTOP TB Partnership TB REACH Wave 6 project STBP/TBREACH/GSA/W6-34
6 · The paper itself

Abstract

backgroundSouth Africa has achieved drug-susceptible TB (DS-TB) treatment success of only 77% among people with new and previously treated TB. Alternative approaches are required to improve medication adherence and treatment completion to limit transmission, TB relapse and the development of resistance. This study aims to implement and evaluate the use of adherence medication monitors (Wisepill evriMED 1000) with a differentiated response to patient care, among DS-TB patients in three provinces of South Africa.

methodsIn total, 18 public health clinics across three provinces were selected. Clinics were randomised to intervention or standard of care clinics. In each clinic, approximately 145 DS-TB patients are being enrolled to reach a total of 2610. All patients have their daily adherence monitored using medication monitors. In the intervention arm, patients are receiving medication monitor reminders and differentiated care in response to adherence data. This weekly review of daily real-time monitoring will be undertaken from a central database. The differentiated care model includes automated SMS reminders with a missed dose, research staff-initiated phone call to the patient with a second or third missed dose, a home visit if four or more doses are missed, and motivational counselling if four or more doses are missed repeatedly. Fidelity of the intervention will be measured through process evaluation. Patients in control clinics will receive medication monitors for adherence tracking, standard of care TB education, and normal clinic follow-up procedures. The primary outcome is the proportion of patients by arm with >80% adherence, as measured by the medication monitor. The feasibility and acceptability of the intervention will be assessed by in-depth interviews with patients, stakeholders, and study staff. A cost effectiveness analysis of the intervention and standard of care clinics will be conducted. SIGNIFICANCE: This trial will provide evidence for the use of an intervention, including medication monitors and differentiated care package, to improve adherence to TB treatment. Improved adherence should also improve TB treatment completion rates, thus reducing loss to follow-up rates, and TB relapse among people with TB. The intervention is intended to ultimately improve overall TB control and reduce TB transmission in South Africa.

trial registrationPan African Trial Registry PACTR201902681157721 . Registered on 11 February 2019.

Indexed as

Medication AdherencePharmaceutical PreparationsAntitubercular AgentsHumansRandomized Controlled Trials as TopicSouth AfricaStandard of CareAntitubercular AgentsPharmaceutical PreparationsMedication adherenceMedication monitorReal-time medication monitoringTuberculosis

Identifiers

PMID34108036
PMCPMC8191030
OpenAlexW3166965929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.